Related Experiment Videos
Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment
1Semiotica and Metodologia Medica, University of Brescia, Italy. agabiti@master.cci.unibs.it
Insights
Left ventricular hypertrophy (LVH) in hypertension is a poor prognostic sign linked to increased cardiovascular events. Reducing LVH may improve outcomes in hypertensive patients.
Area of Science:
- Cardiology
- Hypertension Research
- Clinical Medicine
Background:
- Left ventricular hypertrophy (LVH) in hypertensive patients is a significant predictor of cardiovascular morbidity and mortality.
- LVH is associated with adverse pathophysiological changes, including impaired cardiac function and increased arrhythmia risk.
Purpose of the Study:
- To highlight the prognostic implications of LVH in hypertension.
- To discuss the pathophysiological mechanisms linking LVH to cardiovascular risk.
- To emphasize the therapeutic goal of LVH regression for improved patient outcomes.
Main Methods:
- Clinical recognition of LVH through electrocardiography and echocardiography.
- Review of pathophysiological changes associated with hypertensive LVH.
- Analysis of the relationship between LVH and cardiovascular risk factors.
Main Results:
- LVH independently predicts cardiovascular morbidity and mortality in hypertensive individuals.
- Pathophysiological changes include diastolic dysfunction, reduced coronary flow reserve, arrhythmias, and altered autonomic activity.
- These factors contribute to the increased cardiovascular risk observed in patients with LVH.
Conclusions:
- Regression of LVH should be a primary treatment objective in hypertensive patients.
- Achieving LVH regression may lead to improved cardiovascular prognosis.
- Understanding the mechanisms of LVH is crucial for effective hypertension management.
Abstract:
The presence of left ventricular hypertrophy (LVH) in hypertensive patients, recognized clinically by electrocardiography or echocardiography, is an adverse prognostic sign and a powerful predictor of cardiovascular morbidity and mortality, independent of blood pressure and other cardiovascular risk factors. Several pathophysiological changes accompany the myocytic growth and fibrosis that characterize hypertensive LVH and have been invoked to explain the association of LVH with increased cardiovascular risk. These include: impairment of diastolic function, and probably also of systolic performance, at least during exercise; reduced coronary blood flow reserve; predisposition to ventricular arrhythmias; alteration in cardiac autonomic nervous system activity. All these data have led to the opinion that regression of LVH should be a major goal in the treatment of hypertensive patients and might predict an improvement in prognosis.